Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC, 27599-7295, USA.
Int J Clin Oncol. 2018 Oct;23(5):957-964. doi: 10.1007/s10147-018-1299-y. Epub 2018 May 26.
The aim of this study was to identify the clinical predictors related to the risk of high-grade papillary bladder cancer before first-time transurethral resection of a bladder tumor (TUR-Bt), and to develop and validate a nomogram predicting the risk of high-grade papillary bladder cancer.
A retrospective clinical study of consecutive patients who underwent first-time TUR-Bt for papillary bladder cancer was performed. Medical records were reviewed uniformly, and the following data were collected: age, sex, episodes of urinary symptoms, tumor size, number of tumors, location of the largest tumor (lateral walls, base, posterior wall, dome, and anterior wall), tumor appearance (papillary or non-papillary, pedunculated or sessile), and urinary cytology. Data from 254 patients (Group A) were used for the development of a nomogram, while data from 170 patients (Group B) were used for its external validation.
High-grade papillary bladder cancer was pathologically diagnosed in 51.6 and 74.6% of Group A and Group B patients, respectively. Based on univariable analyses in Group A, macrohematuria, tumor size, multiple tumors, appearance, and positive urinary cytology were selected as variables to incorporate into a nomogram. The AUC value was 0.81 for the internal validation (Group A), and 0.78 for the external validation (Group B). This novel nomogram can predict high-grade papillary bladder cancer accurately.
The present nomogram can help clinicians calculate the probability in patients with bladder cancer before TUR-Bt and decide on earlier intervention and priorities for the treatment of patients diagnosed with bladder cancer.
本研究旨在确定首次经尿道膀胱肿瘤切除术(TUR-Bt)前与高级别乳头状膀胱癌风险相关的临床预测因素,并开发和验证预测高级别乳头状膀胱癌风险的列线图。
对行首次 TUR-Bt 治疗的乳头状膀胱癌连续患者进行回顾性临床研究。统一回顾病历,收集以下数据:年龄、性别、尿路症状发作次数、肿瘤大小、肿瘤数量、最大肿瘤位置(侧壁、底部、后壁、穹窿和前壁)、肿瘤外观(乳头状或非乳头状、有蒂或无蒂)和尿细胞学。254 例患者(A 组)的数据用于开发列线图,而 170 例患者(B 组)的数据用于外部验证。
A 组和 B 组分别有 51.6%和 74.6%的患者病理诊断为高级别乳头状膀胱癌。基于 A 组的单变量分析,肉眼血尿、肿瘤大小、多个肿瘤、外观和阳性尿细胞学被选为纳入列线图的变量。内部验证的 AUC 值为 0.81(A 组),外部验证的 AUC 值为 0.78(B 组)。该新列线图可准确预测高级别乳头状膀胱癌。
本列线图有助于临床医生在 TUR-Bt 前计算膀胱癌患者的概率,并决定对膀胱癌患者进行早期干预和治疗优先级。